Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety
- Inhibrx Biosciences’ ozekibart showed 52% reduced disease progression risk in chondrosarcoma, driving a 70% post-market stock surge. - Combination trials in colorectal and Ewing sarcoma showed 23%–64% response rates, suggesting broader oncology potential. - Hepatotoxicity concerns led to monitoring strategies, reducing adverse events to 11.8% in ozekibart group. - Company plans 2026 BLA submission; stock surged 63% pre-market after prior 10% decline.
Shares of Inhibrx Biosciences (NASDAQ:INBX) soared by more than 70% in after-hours trading on October 23, 2025, after the company announced encouraging Phase 2 trial data for its investigational cancer therapy ozekibart (INBRX-109) in chondrosarcoma, a rare and aggressive bone malignancy that currently lacks approved systemic treatments, as reported by an
Ozekibart’s safety profile was generally acceptable, though liver toxicity was identified as a significant issue. Early in the study, a fatal liver-related incident led to the adoption of risk mitigation strategies, including excluding patients with advanced liver dysfunction and closely monitoring liver function during the initial treatment cycles. These interventions reduced the rate of treatment-related liver side effects to 11.8% in the ozekibart group versus 4.5% in the placebo group, with most cases being mild or moderate in severity, as detailed in
In addition to chondrosarcoma,
The company intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration in the second quarter of 2026, according to Investing.com. Comprehensive data from the ChonDRAgon study will be presented at the Connective Tissue Oncology Society Annual Meeting on November 14, 2025, as noted by Tokenist.
The market responded strongly to the announcement, with
Financially, Inhibrx has a market capitalization near $457 million and maintains strong liquidity, with a current ratio close to 5, according to
INBX shares have climbed 140% year-to-date, reflecting strong investor confidence, though some warn that commercial success will depend on overcoming regulatory challenges and proving long-term effectiveness. With no approved therapies for chondrosarcoma, ozekibart’s potential to be first to market has drawn parallels to other breakthrough drugs in specialized oncology fields, according to Stocktwits.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
PENGU USDT Sell Alert and Stablecoin Price Fluctuations: Evaluating Algorithmic Dangers Amid Changing Cryptocurrency Markets
- PENGU USDT's 2025 volatility reignited debates on algorithmic stablecoin fragility amid regulatory uncertainty and post-UST market skepticism. - Technical analysis showed conflicting signals: overbought MFI vs bearish RSI divergence, with critical support/resistance levels at $0.010-$0.013. - $66.6M team wallet outflows and 32% open interest growth highlighted liquidity risks, while UST's collapse legacy exposed algorithmic design flaws. - Investors increasingly favor fiat-backed alternatives like USDC ,
HYPE Token Experiences Rapid Growth in December 2025: Evaluating Authenticity and Investment Opportunities Amidst an Unstable Post-ETF Cryptocurrency Landscape
- HYPE token surged in Dec 2025 amid post-Bitcoin ETF crypto optimism , raising questions about its investment legitimacy. - Hyperliquid's 72.7% decentralized trading volume share and $106M monthly revenue highlight its DeFi infrastructure strength. - Institutional backing from Paradigm and a $1B DAT fund signals confidence, though major exchange listings remain pending. - Price volatility, token unlocks, and mixed expert opinions underscore risks, with potential $53–$71 targets contingent on market condit
LUNA Falls by 5.77% Over 24 Hours Despite Fluctuating Medium-Term Performance
- LUNA fell 5.77% in 24 hours to $0.1512, but rose 47.52% in 7 days and 105.96% in 30 days. - However, it still faces a 64.14% annual loss, highlighting crypto market volatility and long-term risks for investors. - The price swing reflects sensitivity to macroeconomic shifts and sentiment, with analysts noting ongoing uncertainty in forecasts. - Investors are weighing recent resilience against regulatory challenges and institutional behavior shifts, monitoring if the drop signals a bearish trend or tempora
The Downfall of ChainOpera AI Token: An Alert for AI-Based Cryptocurrency Investments
- ChainOpera AI (COAI) token's 96% collapse in late 2025 highlights systemic risks in AI-driven crypto assets, prompting reevaluation of governance and regulatory frameworks. - Centralized ownership (88% by top 10 holders) and governance flaws at C3.ai exacerbated volatility, undermining decentralization and investor trust. - The crisis triggered sector-wide sell-offs, shifting capital to meme coins, while 2025 regulatory penalties rose 417% to $1.23B, intensifying scrutiny. - Experts warn speculative AI-c
Trending news
MoreCrypto prices
More
